EL7.AI
StocksMedium•19 November 2026•
4 min read

iSpecimen faces Nov. 25 Nasdaq deadline amid financial compliance challenges

Key Facts

1iSpecimen has until Nov. 25, 2026, to demonstrate compliance with Nasdaq’s shareholders’ equity rule.
2Shareholders approved the reverse-split proposal with 1,152,016 votes in favor, 142,944 against and 868 abstentions.
3ISPC shares closed at 0.5331 dollars on Nov. 18, 2026.
4Revenue for the nine months ended Sept. 30, 2026, fell about 71% year over year.

iSpecimen faces a Nov. 25 deadline to demonstrate compliance with Nasdaq’s shareholders’ equity requirement after the exchange granted it an extension for that purpose, according to the company’s filing with the U.S. Securities and Exchange Commission. The deadline comes on the day a report was published about a reverse stock split, but the split ratio and its effective date and time could not be verified through a reliable open source. The company said failure to demonstrate compliance in its periodic report for the fiscal year ended Dec. 31, 2026, could expose it to delisting. That puts its financial position and listing requirements at the center of attention surrounding the stock. The company did not say in the available filing that the split was a means of compliance or specify its connection to the shareholders’ equity deadline.

Nasdaq Rule 5550(b) allows the requirement to be met through one of three alternatives, according to the filing: shareholders’ equity of at least 2,500,000 dollars, a market value of listed securities of at least 35,000,000 dollars, or net income from continuing operations of at least 500,000 dollars. Each alternative is a separate standard under the rule, the company said. The filing linked the Nov. 25 deadline to demonstrating compliance with the rule, not to a minimum share price. It also said failure to demonstrate compliance when filing the periodic report for the year ended Dec. 31, 2026, could expose the company to delisting. The available filing did not report a final result showing that any of the alternatives had been met.

The company’s shareholders approved the reverse-split proposal in an Oct. 30 vote, according to a later company filing. The proposal received 1,152,016 votes in favor, 142,944 against and 868 abstentions, and the company said it had been approved. The vote confirms authorization for the proposal, but does not by itself establish the ratio or implementation date cited in the report published today. The 1-to-6 ratio and effective time of 4:30 p.m. therefore remain unconfirmed here by a reliable open source. The quoted filing did not directly link the vote to any specific alternative for financial compliance.

EL7 data showed that the company’s shares, which trade under the ticker ISPC, closed at 0.5331 dollars on Nov. 18. They had closed at 0.6965 dollars on Nov. 12, placing the two recorded closes six calendar days apart in the context of monitoring the stock’s performance. Verified data available here do not include the session low and high for Nov. 18, so the trading range cited in the report cannot be confirmed. The recorded closing price came ahead of Nasdaq’s deadline scheduled for the following week. The available data did not include a share-price reaction in the Nov. 19 session.

The company’s results for the nine months ended Sept. 30 provide financial context for the risks tied to the Nasdaq deadline. iSpecimen said revenue fell about 71% from the same period a year earlier, despite reporting third-quarter revenue of 244,034 dollars, compared with 106,592 dollars in the same quarter of 2025, an increase of 129%. The figures in its report show quarterly revenue moving in a different direction from revenue for the nine months as a whole. The report did not specify the reason for this difference in the available quotation. These figures cover periods ended Sept. 30 and do not represent results for the period that followed.

The company recorded a net loss of 5,850,026 dollars in the first nine months of 2026, compared with a loss of 5,486,287 dollars in the same period of 2025. Cash and cash equivalents stood at 5,556,914 dollars on Sept. 30, while the accumulated deficit reached 88,200,175 dollars. The company disclosed substantial doubt about its ability to continue as a going concern, alongside positive working capital of 870,936 dollars on the same date. The filing thus combines existing liquidity with a large accumulated deficit and losses during the period, without the figures cited alone resolving the path to compliance with the rule. The next deadline specified in the filing remains Nov. 25 for demonstrating compliance with Nasdaq.

Open on chart